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THERAPEUTIC CYCLOSPORINE (CSA) MONITORING AFTER ALLOGE-
NEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT): HIGH-
PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) OR TDX?
Triﬁlio, S., Borensztajn, J., Mehta, J. Northwestern Memorial Hospital,
Chicago.
CsA level ranges for GVHD prophylaxis have been developed
based on HPLC which estimates the parent (active) drug, but is
cumbersome. TDx, a monoclonal antibody assay for CsA, is
quicker but also measures some of the metabolites which are
biologically inactive. An internal feasibility study was done to
consider switching from HPLC to TDx. 72 blood samples from 6
HSCT recipients (5-19 each) submitted for routine HPLC testing
were also subjected to TDx. There was no charge for TDx. Only
HPLC results were available for clinical use. There was strong
correlation between HPLC and TDx results for the whole group
(r  0.92; P  1029), and for each patient individually (r 
0.75-0.99; P  0.002 to 108). The regression model was:
HPLC  0.55TDx-14.38. The mean (SD) TDx and HPLC levels
were 675 (251) and 359 (149). The TDx/HPLC ratio was 1.34-
2.67 (median 1.92). There was no relationship between the TDx/
HPLC ratio and time from starting CsA, BUN, creatinine, biliru-
bin, albumin, ALT, AST, or alkaline phosphatase. When HPLC
was calculated (c-HPLC) from TDx using a simpliﬁed bedside
formula (c-HPLC  TDx/1.9), the difference between c-HPLC
and actual HPLC (a-HPLC) was -29% to 41% (median 1%).
51% of the paired readings differed by10%, and 14% by20%.
Assuming 200-400 as the therapeutic range, 31 a-HPLC readings
required dose adjustment (8 increase, 23 decrease) compared with
28 c-HPLC (6 increase, 22 decrease). Actions (increase, decrease,
or no change) suggested by a-HPLC and c-HPLC were concor-
dant in 59 cases and discordant in 13 (18%). Discordance was
deﬁned as “potentially critical” (change suggested by a-HPLC but
no change suggested by c-HPLC) in 8 instances, and “not critical”
in 5 (change suggested by c-HPLC and no change suggested by
a-HPLC; where a % change in c-HPLC towards normal when
applied to a-HPLC would not have resulted in a-HPLC going out
of the therapeutic range). Our data show that while there is con-
siderable intra-patient variability in the TDx/HPLC ratio, the
correlation between HPLC and TDx is very strong. TDx can be
substituted for HPLC with a sutiable modiﬁcation in the therapetic
range (380-760 here). Using TDx in our practice is unlikely to
result in the CsA level deviating from the therapeutic range most
of the time; including in patients with severe liver and/or kidney
dysfunction. It must be emphasized that in practice, therapeutic
CsA monitoring usually plays a secondary role to the clinical
picture (evidence of drug toxicity and GVHD).
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TACROLIMUS (FK-506) AND MYCOPHENOLATE MOFETIL (MMF) GVHD
PROPHYLAXIS IN PEDIATRIC ALLOGENEIC SCT (ALLOSCT) RECIPI-
ENTS: ALTERED MMF PHARMACOKINETICS (PK) ASSOCIATED WITH
ACUTE (A)GVHD
Bessmertny, O., Farris, K., van de Ven, C., Harrison, L., Osunkwo, I.,
Wolownik, K., Garvin, J., George, D., Del Toro, G., Bradley, M.B.,
Cheung, Y.-K., Skerrett, D., Cairo, M.S. Children’s Hospital of New
York-Presbyterian, Columbia University, New York, NY.
FK-506/MMF is an effective salvage therapy for steroid-refrac-
tory chronic (C)GVHD (Mookerjee et al, BMT:24:517, 1999) and
prophylaxis of A and CGVHD following nonmyeloablative and
fully ablative conditioning in adults (Rini et al, JCO, 2002; Pavletic
et al Blood, 2002; McSweeney et al, Blood, 2002). We investigated
the safety and efﬁcacy of a FK-506/MMF regimen for AGVHD
prophylaxis in 47 patients (mean age 8.5 yrs [range 0.5-21 yrs]; 31
M, 16 F) undergoing 51 AlloSCTs for hematologic malignancies
(n  27), non-malignant disorders (n  16), and neuroblastoma
(n  4). FK-506 was given 0.03 mg/kg/day continuous IV on Day
-1 or 1st day of conditioning plus MMF 15 mg/kg/dose PO/IV
BID starting Day 1. Doses were adjusted to maintain trough
steady state concentrations within reference ranges of 5-20 ng/mL
for FK-506 and 1-3.5 mcg/mL for mycophenoleic acid (MPA).
HLA typing was low resolution for A, B and C and high resolution
for DR alleles. Stem cell sources: 6/6 UCB (n  4), 6/6 related (R)
UCB (n  1), 5/6 UCB (mismatch: class I [n  8]), 4/6 UCB
(mismatch: class I [n  9], class II [n  2], class I/II [n  8]), 6/6
RBM (n 6), 5/6 RBM (mismatch: class I [n 1], class II [n 1]),
6/6 RPBSCT (n  10), 10/10 unrelated PBSCT (n  1). Condi-
tioning types were: reduced intensity (n  25) and myeloablative
(n  26). Mean time to ANC 500/mm3 x 2 days (n  42) was
13.8  1.7 days and 25.9  17 days following RPBSCT/BM and
UCB, respectively. Mean time to platelet engraftment (20K/
mm3 x 7 days) was 14.7 6 days for RPBSCT/BM and 61.3 57.7
days for UCB recipients. Mean follow up was 324 days (17-989).
Among 39 evaluable transplants, Kaplan-Meier probability of de-
veloping grade II AGVHD was 43.7  8% (36.1  10.4% for
UCB and 56.2  12.4% for MFD recipients) and CGVHD was
38  20% at 18 mos. FK-506/MMF were well tolerated, with 1
episode of grade IV hyperglycemia and 3 episodes of grade III-IV
neurotoxicity. Probability of 1-year OS was 56  12%. Probability
of developing grade II AGVHD was 36.2  13.1% for patients
who achieved MPA trough 1 mcg/mL prior to Day 30 vs
85.7  13.2% for those who did not (p  0.017). These results
suggest that FK506/MMF is a safe and effective GVHD prophy-
laxis regimen following related and unrelated AlloSCT in children.
Subtherapeutic MPA trough concentrations are associated with a
signiﬁcantly increased incidence of grade II AGVHD. Further
MMF pharmacokinetic/pharmacodynamic studies are ongoing in
pediatric AlloSCT recipients to deﬁne the optimal dose and sched-
ule of MMF.
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SHOULD SERUM VORICONAZOLE (VORI) LEVELS BE MONITORED IN
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT) RE-
CIPIENTS?
Triﬁlio, S.1, Ortiz, R.1, Pennick, G.2, Pi, J.1, Verma, A.1, Mehta, J.1
1. Northwestern University, Chicago; 2. UT Health Science Center, San
Antonio.
Vori has signiﬁcant activity against Candida and Aspergillus. It is
metabolized by the hepatic cytochrome P450 enzymes 2C19, 2C9
and 3A4. CYP2C19, which plays a signiﬁcant role in the metabo-
lism, exhibits signiﬁcant genetic polymorphism. As a result, some
patients metabolize Vori poorly. The clinical signiﬁcance of this
and resultant possible increases in Vori levels is unknown, and the
utility of monitoring Vori levels is unclear. We monitored steady-
state trough serum Vori levels in 22 allogeneic HSCT recipients
using a new HPLC assay (Pennick et al. Antimicrob Agents Che-
mother 2003;47:2348-50). All had received non-myeloablative
conditioning with 100 mg/m2 melphalan (50 mg/kg cyclophos-
phamide if not prior autograft). GVHD prophylaxis comprised
cyclosporine/tacrolimus with mycophenolate mofetil. Vori was
started at 200 mg BID PO in 20 patients, and 400 mg BID for a day
followed by 200 mg BID in 2. One had aspergillosis, and the rest
were receiving Vori prophylactically or empirically. Patients had
drug levels checked once (n  12), twice (n  8), or 3 times (n 
2); 5 days to 9 months (median 10 days) after starting Vori or dose
modiﬁcation. The intention was to achieve a level greater than
0.5-1.0 g/mL corresponding to the in vitro MIC90 of Vori for
Aspergillus spp. The 22 baseline levels ranged from 0.2 to 6.8
g/mL (median 1.1). Overall, the 36 levels were 0.2-6.8 (median
1.7); with 5 levels 0.5. An increase in the dose to 300 mg twice
daily in 3 patients (2 with levels0.5 and 1 with a level of 1.0 in the
presence of aspergillosis) increased the level 6- to 8-fold. There
was no signiﬁcant correlation between Vori levels and serum cre-
atinine, bilirubin, and ALT. Vori levels correlated with alkaline
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phosphatase (r  0.44; P  0.008) and AST (r  0.52; P  0.001).
Since liver dysfunction is relatively common after allogeneic
HSCT, it was not possible to determine if elevated AST and
alkaline phosphatase levels were the cause or the consequence of
higher Vori levels. Based on these data, we conclude that trough
Vori levels vary considerably between patients with a small pro-
portion having potentially subtherapeutic levels on standard doses.
We suggest checking serum Vori levels in patients receiving the
drug for conﬁrmed fungal infections. Additionally, patients devel-
oping elevation of AST or alkaline phosphatase on therapy should
also have Vori levels monitored. Vori levels should also be checked
if the drug dose is changed.
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RESULTS OF ONCE DAILY PARENTERAL BUSULFAN (BUSULFEX)
WITH CYCLOPHOSPHAMIDE VERSUS INTERMITTENT DOSING OF
BUSULFAN WITH CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN
FOR ALLOGENEIC TRANSPLANT RECIPIENTS WITH UNDERLYING HE-
MATOLOGICAL MALIGNANCIES AND DISEASES
Mamlouk, K.1, White, M.J.2, Berryman, R.B.2, Fay, J.W.2,
Pineiro, L.A.2, Vance, E.A.2, Agura, E.A.2 1. Baylor University Med-
ical Center, Dallas, TX; 2. Baylor Sammons Cancer Center and Texas
Oncology.P.A., Dallas, TX.
The use of high dose oral busulfan has been a standard treatment
regimen employed in the ﬁeld of blood and marrow transplanta-
tion for over 30 years. The toxicity proﬁle of high dose busulfan
includes hematological, neurological and hepatic dysfunction. At
doses of 16 mg/kg, the hematological toxicity requires stem cell
rescue. Neurologic toxicity is mild, but has led to the routine use
of phenytoin for seizure prophylaxis. The other principal toxicity
of high dose busulfan is hepatic complications, primarily described
as veno-occlusive disease (VOD).
Historically, high dose busulfan has been administered orally
over four days in a QID dosing schedule. The rationale for this
dosing interval was primarily due to the large numbers of tablets
patients had to swallow for a typical dose (i.e. a 70kg person would
have to swallow 560 tablets). Additional concerns due to hepatic
ﬁrst-pass metabolism have been associated with inter-patient vari-
ation in plasma levels.
The initial trials of a parenteral formulation of IV busulfan were
designed to duplicate the oral dosing experience, and it was deter-
mined that 0.8 mg/kg every 6 hours X 16 doses was an equivalent
dosing regimen. However, many transplant centers are exploring
the feasibility of using once daily dosing (3.2 mg/kg daily times 4
days) versus the conventional dosing regimens.
To date, we have enrolled 13 of 20 anticipated patients on an IRB
approved protocol using once daily dosing of IV busulfan. These
patients will be compared to historical controls who received in-
termittent dosing. Pharmacokinetic monitoring is being performed
using the WINNONLIN® program. The primary objectives of
the study are to compare hematopoietic engraftment, incidence
and severity of VOD, interstitial pneumonitis, and seizure occur-
rence during drug administration.
A preliminary analysis of the ﬁrst 10 patients has not demon-
strated any acute toxicities, and only one of the 10 patients has
required a dosage adjustment.
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ELEVATED PLASMA LEVELS OF TACROLIMUS AFTER CONCURRENT USE
OF TACROLIMUS AND VORICONAZOLE IN THE BONE MARROW TRANS-
PLANT SETTING
Cool, R.M., Ippoliti, C., Cuellar, S., Donato, M.L. University of Texas
MD Anderson Cancer Center, Houston, TX.
Voriconazole is a broad-spectrum triazole antifungal agent used
for the prevention and treatment of invasive fungal infections in
high-risk transplant recipients. Azole antifungal agents have been
associated with numerous drug-drug interactions. Voriconazole is
extensively metabolized through the liver via the cytochrome
(CYP) P450 enzyme system. The primary isoenzymes involved are
CYP2C19, CYP2C9 and CYP3A4. Patients undergoing allogeneic
stem cell transplantation at MD Anderson Cancer Center receive
tacrolimus for graft versus host disease prophylaxis, dosed to
achieve therapeutic plasma levels between 5-12 ng/ml. Reports in
the literature have demonstrated the concurrent use of tacrolimus
and voriconazole to result in supra-therapeutic tacrolimus levels in
liver transplant recipients. Supra-therapeutic tacrolimus levels have
been associated with adverse events such as renal failure requiring
hemodialysis and seizures. The primary objective of this study was
to determine the effect of voriconazole on tacrolimus levels in the
bone marrow transplant setting. We performed a retrospective
chart review of 30 bone marrow and stem cell transplant recipients
who received concurrent therapy with voriconazole and tacroli-
mus. Data collected included patient demographics, diagnosis, type
and date of transplant, concomitant medications, and pertinent
laboratory tests (serum creatinine, blood urea nitrogen, liver func-
tion tests, and tacrolimus levels). The dose of voriconazole was as
follows: 200 mg po BID (n  18), 200 mg po QD (n  1), 200 mg
IV q12h (n  4), and 3-4 mg/kg IV q12h (n  7). Preliminary
results reveal that 22 patients (73%) experienced an increase in
plasma levels of tacrolimus, which occurred at a median of 5 days
(range 2-10 days) of concomitant therapy. Over one-half of these
patients had more than a 75% increase in plasma tacrolimus levels
thus requiring a signiﬁcant decrease in tacrolimus dose. Of the 22
patients, 7 (32%) showed mild to moderate elevations in liver
function tests which may have contributed to supra-therapeutic
tacrolimus levels due to the drug’s extensive hepatic metabolism.
While the manufacturer recommends that the tacrolimus dose be
reduced to one-third of the original dose when initiating therapy
with voriconazole in patients already receiving tacrolimus, our
initial results suggest that some patients may require up to a 75%
decrease in tacrolimus dose to avoid supra-therapeutic levels of
tacrolimus and subsequent sequelae.
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RETROSPECTIVE REVIEW OF THERAPY WITH REDUCED DOSE RAS-
BURICASE IN ADULTS WITH HYPERURICEMIA ASSOCIATED WITH MA-
LIGNANCY
Hutcherson, D.A., Sessions, J.K., Mihelic, R.A., Shayani, S.,
Barreras, A.M., Bucur, S.Z., Heffner, L.T., Langston, A.A. Emory
University Hospital, Winship Cancer Institute, Atlanta, GA.
Here we report our institutional experience in the treatment of
malignancy-related hyperuricemia with reduced dose IV ras-
buricase. Eight patients with various underlying diseases (AML(3),
Burkitt’s NHL (2), ALL (1), MDS (1), MM (1) and CLL/Richter’s
transformation (1)) received 9 treatments (6 mg IV over 30 min-
utes) of rasburicase. Rasburicase was given as a single dose except
in one patient who received a second 6 mg dose early during the
chemotherapy cycle for persistent elevated uric acid levels. Another
patient was retreated with their subsequent cycle of chemotherapy
eight days later. The 6 mg doses of rasburicase for each patient
ranged from 0.05 to 0.1 mg/kg. Patient ages ranged from 46-74
years (mean 62) and patients either had developed or were deemed
at high risk for developing renal dysfunction. Pre-treatment uric
acid levels ranged from21 (2 patients) to 8.7 mg/dL (mean14.6
mg/dL) and pre-therapy serum creatinine levels ranged from 9.9 to
1.1 mg/dL (mean 3.3 mg/dL). As part of standard of care for tumor
lysis, all patients received hyperhydration / alkalinization, pro-
phylactic allopurinol and monitoring of uric acid levels. The single
6 mg dose rapidly reduced uric levels to normal limits (8.3). Uric
acid reductions were observed as follows: 21 to 13.0 @ 17.3h
(patient then received a second dose), 21 to 5.3 @ 38.2h, 16.4 to
5.6 @ 10.3h, 15.1 to 3.3 @ 22.5 h, 15.2 to 4.0 @ 12.1h, 14.1 to 6.6
@ 23.8h, 11.1 to 0.9 @ 20.5h, 9.0 to 2.9 @ 11.5h and 8.7 to 1.2 @
32h. We conclude, that a single 6 mg dose of rasburicase is
sufﬁcient to rapidly reduce hyperuricemia of malignancy and pro-
vides adequate and cost-effective treatment for hyperuricemia from
tumor lysis in adults.
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